Trials Sponsors Conditions Drugs Pricing

Conditions

Cirrhosis Decompensated Cirrhosis of Liver

Keywords

Non-Selective Beta-BlockersDecompensated CirrhosisTarget Trial Emulation

Outcome Measures

Primary Outcomes (1)

All-cause mortality
Death from any cause following discharge after hospitalization for hepatic complications of cirrhosis. Mortality data will be obtained through death registry linkage. Hazard ratios (HR) will be calculated using Cox proportional hazards models, adjusted for demographic factors, comorbidities, medications at discharge, health behaviors, and admission-related variables.
1 month, 3 months, 6 months, and 1 year after discharge from index hospitalization

Secondary Outcomes (2)

All-cause hospital readmission
1 month, 3 months, 6 months, and 1 year after discharge from index hospitalization
Hepatic complication-related hospital readmission
1 month, 3 months, 6 months, and 1 year after discharge from index hospitalization

Study Arms (2)

With NSBB

Patients with chronic hepatitis B or C who were hospitalized for hepatic complications (hepatic encephalopathy, hepatorenal syndrome, ascites, or spontaneous peritonitis) and received NSBB prescription at discharge. The study will compare outcomes in this group with the non-NSBB group.

Drug: Non-selective beta-blockers

Without NSBB

Patients with chronic hepatitis B or C who were hospitalized for hepatic complications (hepatic encephalopathy, hepatorenal syndrome, ascites, or spontaneous peritonitis) and did not receive NSBB prescription at discharge. This group will serve as the control group for comparison.

Interventions

Non-selective beta-blockersDrug

Non-selective beta-blockers (NSBB) prescribed at discharge for patients hospitalized with hepatic complications. The study will analyze two types of NSBB: propranolol and carvedilol. The study will also examine potential dosage effects by categorizing NSBB use into low-dose and middle-high dose groups. NSBB use is defined as a prescription for at least 2 days at discharge.

Also known as: Carvedilol, Propranolol

With NSBB

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age19 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The study will include adult patients with liver cirrhosis and chronic hepatitis B or C who were hospitalized due to hepatic complications in South Korea between January 2013 and October 2023. The study will focus on patients who experienced hepatic complications including ascites, peritonitis, hepatorenal syndrome, and hepatic encephalopathy. Both patients who received NSBB at discharge and those who did not will be included in the analysis to allow for comparison between these groups.

You may qualify if:

Sponsors & Collaborators

Samsung Medical Center
Otherlead

Study Sites (1)

Samsung Medical Center

Seoul, South Korea

Related Publications (1)

Song BG, Lee M, Kang D, Kang W, Shim JH, Sinn DH, Gwak GY. Non-Selective Beta-Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation. Aliment Pharmacol Ther. 2026 Jun 22. doi: 10.1111/apt.70807. Online ahead of print.
PMID: 42328960DERIVED

MeSH Terms

Conditions

Fibrosis

Interventions

CarvedilolPropranolol

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesCarbazolesIndoles

Study Officials

Dong Hyun Sinn, MD, PhD
Samsung Medical Center
PRINCIPAL INVESTIGATOR

Enrollment

7,725 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 8, 2025

First Posted

May 18, 2025

Study Start

January 1, 2013

Actual (reported)

Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

With NSBB

Without NSBB

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

With NSBB

Without NSBB

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations